Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04057638

Craniomaxillofacial and Upper Extremity Allotransplantation

The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Langone Health

New York, 10017, United States

Location status: Recruiting

Location contact

Aileen Blitz, MD

SUB_INVESTIGATOR

Allison Rojas, MS, RN

SUB_INVESTIGATOR

Allyson Alfonso, BS

SUB_INVESTIGATOR

Alyssa Golas, MD

SUB_INVESTIGATOR

Arthur Kaplan, PhD

SUB_INVESTIGATOR

Bruce Gelb, MD

SUB_INVESTIGATOR

Daniel Ceradini, MD

SUB_INVESTIGATOR

David Chiu, MD

SUB_INVESTIGATOR

David Staffenberg, MD

SUB_INVESTIGATOR

Eduardo Rodriguez, MD, DDS

PRINCIPAL_INVESTIGATOR

Elie Ramly, MD

CONTACT

[email protected]

929-455-5824

Elie Ramly, MD

SUB_INVESTIGATOR

Jacques Hacquebord, MD

SUB_INVESTIGATOR

Jamie Levine, MD

SUB_INVESTIGATOR

Jonathan Bass, MD

SUB_INVESTIGATOR

Mihye Choi, MD

SUB_INVESTIGATOR

Pierre Saadeh, MD

SUB_INVESTIGATOR

Roberto Flores, MD

SUB_INVESTIGATOR

Sheel Sharma, MD

SUB_INVESTIGATOR

Stephen Ross, MD

SUB_INVESTIGATOR

Thomas Calahan, BA

CONTACT

[email protected]

9294555826

Vishal Thanik, MD

SUB_INVESTIGATOR

About this study

The purpose of this study is to see if an investigational surgery that transfers tissue from a non-living donor to a living individual will help restore greater function, appearance, and sensation to the face and upper extremity areas of individuals who have suffered injury to those areas. Upper extremity constitutes the part of the body including arm, forearm and hand. This procedure is called combined craniomaxillofacial and upper extremity allotransplantation or "combined face and upper extremity transplant".

This study will also collect data on how patients do during and after having a combined face and upper extremity transplant from a nonliving donor. Recovery and outcomes will be observed through clinical exams, x-rays, blood and tissue tests, and other associated evaluations at all follow up visits.

Participants are invited to take part in this research study who have suffered severe injury to the face and upper extremity and previous surgeries to repair the injury have not restored function, appearance, and sensation. Participants must have attempted a trial of prosthetics (artificial upper extremity), if at all possible.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated all required Institutional Review Board (IRB) approved consent forms.
  • Male or female recipient between the ages of 18-64 years. Recipients do not need to be of the same sex as the donor.
  • Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage.
  • Missing part of one or both hands and forearms.
  • Must be HIV negative at the time of transplant.
  • Crossmatch is negative at the time of transplant.
  • Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction.
  • Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in upper extremity reconstruction.
  • Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery.
  • The subject is able to complete pre-transplant examination and screening procedures.
  • Patient has been approved by Patient Selection Committee for placement on the recipient waiting list.
  • The subject is willing to continue immunosuppression regimen as directed by treating physician.
  • Subject is willing and able to return to follow-up visits as described in treatment plan.
  • Subjects must have autogenous tissue options available for reconstruction in event of graft failure.
  • Normal glomerular filtration rate (GFR) >60.
  • Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant.

Exclusion criteria

  • Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation
  • Serious co-morbidities
  • Positive serology for HIV; Hepatitis B Antigen
  • Active malignancy within 5 years with the exclusion of non-melanoma
  • Substance abuse disorders not currently under control (as determined by the Michigan Alcohol Screening Test - see Appendix N.1: Subjects with a score of 3 or more will be excluded)
  • Body Dysmorphic disorder (see Appendix N.2 for screening tool). Less severe psychiatric conditions are addressed on a case by case basis
  • Active Severe Psychiatric Illness
  • Cognitive limitations affecting the patient's ability to provide informed consent
  • Recent history of medical non-adherence
  • Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other.
  • Recent history of medical non-adherence.
  • Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study
  • Currently active smoker within 1 year
  • Subjects with any cognitive deficits related to a traumatic brain injury (TBI) and or any organic neurological disorders
  • Any other psychological status that would hinder the success or safety of the transplantation.
  • Level of amputation proximal to mid-humerus: some presence of proximal muscles is required to motor a functioning hand.
  • Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post-transplant results
  • History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation. This can be waived in cases where the recipient requires amputation/revision of the transplant site at the time of transplantation. However, if at all possible, it is highly encouraged that the patient has ruled out prosthetics as an alternative to transplantation.
  • Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation
  • Pregnancy

Treatment and study plan

Combined Craniomaxillofacial and Upper Extremity Allotransplantation

Procedure

Combined Craniomaxillofacial and Upper Extremity Allotransplantation

Primary outcomes

  1. Change in function of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using electromyogram (EMG)

  2. Change in function of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using nerve conduction studies (NCS)

  3. Change in function of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using computerized tomography angiogram (CTA)

  4. Change in function of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using magnetic resonance imaging (MRI)

  5. Change in function of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using vision exams

  6. Change in function of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using pathology samples to check for rejection

  7. Change in function of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using electromyogram (EMG)

  8. Change in function of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using nerve conduction studies (NCS)

  9. Change in function of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using computerized tomography angiogram (CTA)

  10. Change in function of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using magnetic resonance imaging (MRI)

  11. Change in appearance of the transplanted facial segment

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using photography

  12. Change in appearance of the upper extremity transplant

    Time frame: Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

    This will be measured using photography

Study contacts

Contact information is provided by the study sponsor or research team.

Thomas Calahan, BA

CONTACT

[email protected]

(929) 455-5826

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Combined Craniomaxillofacial and Upper Extremity Allotransplantation

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Aug 15, 2019
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.